These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20627557)

  • 1. Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1.
    Wei L; Gao X; Warne R; Hao X; Bussiere D; Gu XJ; Uno T; Liu Y
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3897-902. PubMed ID: 20627557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-(3-Oxo-1,3-diphenylpropyl)malonic acids as potent allosteric ligands of the PIF pocket of phosphoinositide-dependent kinase-1: development and prodrug concept.
    Wilhelm A; Lopez-Garcia LA; Busschots K; Fröhner W; Maurer F; Boettcher S; Zhang H; Schulze JO; Biondi RM; Engel M
    J Med Chem; 2012 Nov; 55(22):9817-30. PubMed ID: 23106316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3,5-Diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: structure-activity relationships and thermodynamic characterization of binding as paradigms for PIF-binding pocket-targeting compounds.
    Stroba A; Schaeffer F; Hindie V; Lopez-Garcia L; Adrian I; Fröhner W; Hartmann RW; Biondi RM; Engel M
    J Med Chem; 2009 Aug; 52(15):4683-93. PubMed ID: 19606904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site.
    Busschots K; Lopez-Garcia LA; Lammi C; Stroba A; Zeuzem S; Piiper A; Alzari PM; Neimanis S; Arencibia JM; Engel M; Schulze JO; Biondi RM
    Chem Biol; 2012 Sep; 19(9):1152-63. PubMed ID: 22999883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity.
    Islam I; Bryant J; Chou YL; Kochanny MJ; Lee W; Phillips GB; Yu H; Adler M; Whitlow M; Ho E; Lentz D; Polokoff MA; Subramanyam B; Wu JM; Zhu D; Feldman RI; Arnaiz DO
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3814-8. PubMed ID: 17531483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK1 Protein Kinase.
    Schulze JO; Saladino G; Busschots K; Neimanis S; Süß E; Odadzic D; Zeuzem S; Hindie V; Herbrand AK; Lisa MN; Alzari PM; Gervasio FL; Biondi RM
    Cell Chem Biol; 2016 Oct; 23(10):1193-1205. PubMed ID: 27693059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-benzimidazolyl-3-phenylbutanoic acids as novel PIF-pocket-targeting allosteric inhibitors of protein kinase PKCζ.
    Fröhner W; Lopez-Garcia LA; Neimanis S; Weber N; Navratil J; Maurer F; Stroba A; Zhang H; Biondi RM; Engel M
    J Med Chem; 2011 Oct; 54(19):6714-23. PubMed ID: 21863889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments.
    Stockman BJ; Kothe M; Kohls D; Weibley L; Connolly BJ; Sheils AL; Cao Q; Cheng AC; Yang L; Kamath AV; Ding YH; Charlton ME
    Chem Biol Drug Des; 2009 Feb; 73(2):179-88. PubMed ID: 19207420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors.
    Rao AU; Xiao D; Huang X; Zhou W; Fossetta J; Lundell D; Tian F; Trivedi P; Aslanian R; Palani A
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1068-72. PubMed ID: 22182499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a fluorescent ATP analog to probe the allosteric conformational change in the active site of the protein kinase PDK1.
    Hindie V; Lopez-Garcia LA; Biondi RM
    Methods Mol Biol; 2012; 928():133-41. PubMed ID: 22956138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
    Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
    Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The chemical diversity and structure-based discovery of allosteric modulators for the PIF-pocket of protein kinase PDK1.
    Xu X; Chen Y; Fu Q; Ni D; Zhang J; Li X; Lu S
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):361-374. PubMed ID: 30734603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and characterization of "clickable" 4-anilinoquinazoline kinase inhibitors.
    Perera BG; Maly DJ
    Mol Biosyst; 2008 Jun; 4(6):542-50. PubMed ID: 18493651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thieno[3,2-d]pyrimidin-4(3H)-one derivatives as PDK1 inhibitors discovered by fragment-based screening.
    Lee AC; Ramanujulu PM; Poulsen A; Williams M; Blanchard S; Ma DM; Bonday Z; Goh KL; Goh KC; Goh MK; Wood J; Dymock BW
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4023-7. PubMed ID: 22591730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of Rho kinase inhibitors (II).
    Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
    Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fused protein of deltaPKC activation loop and PDK1-interacting fragment (deltaAL-PIF) functions as a pseudosubstrate and an inhibitory molecule for PDK1 when expressed in cells.
    Seki T; Irie N; Nakamura K; Sakaue H; Ogawa W; Kasuga M; Yamamoto H; Ohmori S; Saito N; Sakai N
    Genes Cells; 2006 Sep; 11(9):1051-70. PubMed ID: 16923125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDK1 and PKB/Akt: ideal targets for development of new strategies to structure-based drug design.
    Harris TK
    IUBMB Life; 2003 Mar; 55(3):117-26. PubMed ID: 12822887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric activation of the protein kinase PDK1 with low molecular weight compounds.
    Engel M; Hindie V; Lopez-Garcia LA; Stroba A; Schaeffer F; Adrian I; Imig J; Idrissova L; Nastainczyk W; Zeuzem S; Alzari PM; Hartmann RW; Piiper A; Biondi RM
    EMBO J; 2006 Nov; 25(23):5469-80. PubMed ID: 17110931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIF-pocket as a target for C. albicans Pkh selective inhibitors.
    Pastor-Flores D; Schulze JO; Bahí A; Giacometti R; Ferrer-Dalmau J; Passeron S; Engel M; Süss E; Casamayor A; Biondi RM
    ACS Chem Biol; 2013 Oct; 8(10):2283-92. PubMed ID: 23911092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.